Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare Therapeutics Announces Positive Results from Lunresertib, Camonsertib Combo Trial
Details : RP-6306 (lunresertib), a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, is being developed in combination with Camonsertib for the treatment of endometrial cancer.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Repare Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic
Details : The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 06, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Repare Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare Shares Positive Phase 1 Data From MYTHIC Safety and Tolerability Study
Details : RP-6306 (lunresertib) in combination with RP-3500 (camonsertib) is being evaluated for the treatment of multiple advanced solid tumors types.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare and Debiopharm Dosed First Patient in Phase 1/1b MYTHIC Trial
Details : RP-6306 (lunresertib), an oral PKMYT1 inhibitor, is being developed in combination with Debio 0123, a selective WEE1 kinase inhibitor, for treating advanced solid tumors.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Lunresertib,Debio 0123
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Debiopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repare's Lunresertib Gets FDA Fast Track for Platinum-Resistant Ovarian Cancer
Details : FDA granted Fast Track designation to RP-6306 (lunresertib) in combination with RP-3500 (camonsertib) for CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Lunresertib,Camonsertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Debiopharm Partners with Repare To Explore PKMYT1 and WEE1 Inhibition
Details : This collaboration will explore synergy between Debio 0123, a selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class small molecule with anticancer activity.
Product Name : Debio 0123
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Debio 0123,Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Debiopharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Canadian Cancer Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RP-6306 (lunresertib) is a PKMYT1 inhibitor currently in Phase 1 clinical development a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Canadian Cancer Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data demonstrated inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306 used CRISPR-based screening approach, to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first patient has been dosed in the company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors.
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Lunresertib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The event will focus on RP-6306, a potent and selective inhibitor of a novel target that is synthetic lethal with CCNE-1 amplification. The Company expects to begin a Phase 1 clinical trial in the second quarter of 2021, one quarter earlier than prior gu...
Product Name : RP-6306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Lunresertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable